SYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN Alzheimer’s Test MI Biomarker, For Identifying Alzheimer’s in Presence of Other Co-Morbid Pathologies
ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce its upcoming presentation of “Autopsy-Confirmed Minimally Invasive Biomarker Identifies Alzheimer’s Disease even in the Presence of Co-Morbid Pathologies” at the Alzheimer’s Association International Conference (AAIC), July 31 … [Read more…]
